Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium: A Pilot Study

Abstract

A single subconjunctival bevacizumab injection seems to only partially and transiently decrease conjunctival vascularization in impending recurrent pterygium in a dose-dependent manner. This treatment does not cause regression or reduce the recurrent rate of impending recurrent pterygium.